CORE LABS INC (CLB)
(Delayed Data from NYSE)
$19.18 USD
+0.60 (3.23%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $19.18 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Core Laboratories Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 15 | 18 | 14 | 11 |
Receivables | 123 | 115 | 107 | 93 | 138 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 72 | 60 | 45 | 38 | 50 |
Other Current Assets | 13 | 21 | 19 | 21 | 22 |
Total Current Assets | 223 | 212 | 189 | 166 | 221 |
Net Property & Equipment | 100 | 105 | 111 | 115 | 124 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 69 | 69 | 70 | 73 | 67 |
Intangibles | 106 | 107 | 108 | 108 | 231 |
Deposits & Other Assets | 34 | 34 | 41 | 40 | 56 |
Total Assets | 586 | 578 | 581 | 569 | 775 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 34 | 46 | 30 | 23 | 36 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 25 | 28 | 27 | 33 | 35 |
Income Taxes Payable | 7 | 3 | 7 | 8 | 6 |
Other Current Liabilities | 12 | 14 | 15 | 14 | 23 |
Total Current Liabilities | 88 | 103 | 91 | 90 | 112 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 13 | 23 | 24 | 21 | 27 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 163 | 172 | 189 | 259 | 305 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 51 | 53 | 67 | 67 | 84 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 357 | 389 | 420 | 493 | 593 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 1 | 1 | 1 | 1 |
Capital Surplus | 110 | 102 | 101 | 41 | 52 |
Retained Earnings | 121 | 86 | 68 | 50 | 161 |
Other Equity | 0 | 1 | -6 | -3 | -2 |
Treasury Stock | 1 | 1 | 4 | 14 | 29 |
Total Shareholder's Equity | 230 | 189 | 161 | 76 | 182 |
Total Liabilities & Shareholder's Equity | 586 | 578 | 581 | 569 | 775 |
Total Common Equity | 230 | 189 | 161 | 76 | 182 |
Shares Outstanding | 46.70 | 46.30 | 46.20 | 44.50 | 44.30 |
Book Value Per Share | 4.92 | 4.08 | 3.48 | 1.70 | 4.11 |
Fiscal Year End for Core Laboratories Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 18 | 15 | 15 | 17 | 26 |
Receivables | 131 | 130 | 123 | 121 | 121 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 70 | 71 | 72 | 75 | 72 |
Other Current Assets | 15 | 14 | 13 | 15 | 17 |
Total Current Assets | 234 | 229 | 223 | 229 | 236 |
Net Property & Equipment | 99 | 99 | 100 | 100 | 102 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 71 | 66 | 69 | 72 | 69 |
Intangibles | 106 | 106 | 106 | 107 | 107 |
Deposits & Other Assets | 33 | 34 | 34 | 32 | 33 |
Total Assets | 598 | 588 | 586 | 592 | 602 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 37 | 32 | 34 | 34 | 39 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 24 | 25 | 23 | 25 |
Income Taxes Payable | 8 | 4 | 7 | 5 | 7 |
Other Current Liabilities | 15 | 14 | 12 | 13 | 14 |
Total Current Liabilities | 98 | 85 | 88 | 84 | 96 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 13 | 13 | 13 | 12 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 148 | 160 | 163 | 178 | 183 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 51 | 51 | 48 | 49 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 352 | 351 | 357 | 363 | 382 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 113 | 115 | 110 | 109 | 108 |
Retained Earnings | 132 | 124 | 121 | 119 | 110 |
Other Equity | 0 | 0 | 0 | 1 | 1 |
Treasury Stock | 0 | 1 | 1 | 0 | 0 |
Total Shareholder's Equity | 246 | 237 | 230 | 229 | 220 |
Total Liabilities & Shareholder's Equity | 598 | 588 | 586 | 592 | 602 |
Total Common Equity | 246 | 237 | 230 | 229 | 220 |
Shares Outstanding | 46.90 | 46.90 | 46.70 | 46.70 | 46.60 |
Book Value Per Share | 5.24 | 5.06 | 4.92 | 4.91 | 4.71 |